DDInter843 DDInter899
An antifungal antibiotic. Griseofulvin may be given by mouth in the treatment of tinea infections.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Griseofulvin {u} (Compound) binds {v} (Gene) KRT12
Griseofulvin {u} (Compound) is included by {v} (Pharmacologic Class) Decreased Mitosis
Griseofulvin {u} (Compound) downregulates {v} (Gene) CCDC86
Griseofulvin {u} (Compound) causes {v} (Side Effect) Neuropathy peripheral
Griseofulvin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Bortezomib
Griseofulvin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dolutegravir
Griseofulvin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Naloxegol
Griseofulvin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Mirtazapine
Griseofulvin {u} may lead to a major life threatening interaction when taken with {v} Norgestimate
Griseofulvin {u} may lead to a major life threatening interaction when taken with {v} Etonogestrel
Griseofulvin (Compound) binds KRT12 (Gene)
Griseofulvin (Compound) is included by Decreased Mitosis (Pharmacologic Class)
Griseofulvin (Compound) downregulates CCDC86 (Gene)
Griseofulvin (Compound) causes Neuropathy peripheral (Side Effect)
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Bortezomib
Griseofulvin may cause a minor interaction that can limit clinical effects when taken with Dolutegravir
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol
Griseofulvin may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine
Griseofulvin may lead to a major life threatening interaction when taken with Norgestimate
Griseofulvin may lead to a major life threatening interaction when taken with Etonogestrel